Close this search box.

Successful production of recombinant human serum albumin (rHSA) by the BioTech division

ARTES Biotechnology and Basic Pharma are almost there! Our joint project for the production of recombinant human serum albumin (rHSA) is nearing completion and the first product is expected to be available this summer.

Basic Pharma is well established in the development, production, and licensing of (bio)pharmaceutical products and is now entering the biotech market with its recombinant protein production facilities. Our partner ARTES specializes in the development and transfer of microbial cell lines and protein production processes for recombinant proteins.

We are pleased to announce today that our strategic collaboration is working extremely well, and the project is nearing completion.

rHSA expressed from Hansenula polymorpha will be launched this summer. Target groups for our product include laboratories in academia and industry in need of high-quality recombinant proteins for their research projects. We will be delighted to hear from you.

Read our full press release here.